Lv1
80 积分 2025-04-16 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
9小时前
待确认
How GLP-1 went from being a hard-to-handle hormone to a blockbuster success
11小时前
已完结
Cubanes in Medicinal Chemistry
20天前
已完结
Structural insight into selectivity of amylin and calcitonin receptor agonists
1个月前
已完结
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
1个月前
已完结
Amylin receptor subunit interactions are modulated by agonists and determine signaling
1个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
1个月前
已完结
The evolution of the obesity drug market
1个月前
已完结
Amylin takes another shot at the obesity prize
1个月前
已完结
Urticaria
2个月前
已完结
皖公网安备34019202002308
